Emerging Wound Care Therapy Now Heals Limbs Previously Scheduled for Amputation

WASHINGTON, Aug. 14, 2019 /PRNewswire/ — AVANTI Technologies Inc. (AVANTI) nursing team supports Los Angeles medical device company, Numotech Inc., to address one of health care’s biggest challenges – nonhealing wounds that up until now often led to limb amputations. The Numobag® Kit, a wound treatment solution proven to heal severe wounds in record time, was utilized by AVANTI’s dedicated nurses to save an elderly patient’s limb which was scheduled for amputation. One major result is the significant elimination of many amputations representing both an enormous and growing costly healthcare problem in the United Sates and throughout the world. See the Numobag® website: (https://www.numobag.com).

A recent clinical study entitled “A Disruptive Treatment to Prevent Amputation and Enhance Limb Salvage in an Elderly Patient” profiles a 95-year-old patient presented with a stage IV chronic and advance infected wound on her lower left leg. Medical tests revealed a life-threatening condition that was leading to a potential amputation of her left leg. After extensive and intensive traditional wound therapies were unsuccessful, the introduction of an adjunctive treatment was made with topical hyperbaric oxygen therapy (THOT®) that saw complete healing of the wound within 15 weeks. The wound closed, without the presence of scar tissue, and there were no signs of wound breakdown at three- and six-month follow-ups, thus eliminating the need for amputation.

Therapy innovator Numotech, Inc. is a medical device manufacturer that develops and produces low-cost cutting-edge wound treatment medical devices to meet a wide range of unmet wound care needs, and the Numobag® is the first of its FDA approved medical products to be put into full patient care service. AVANTI provides the nursing, clinical training and support for the Numobag®. The innovative product is a lightweight, portable and disposable membrane for one-time use only. As a medical device innovation, the Numobag® significantly advances the use of low-pressure oxygen as a drug and takes oxygen therapy to the next level of effectiveness, thus quickly promoting blood vessel growth and angiogenesis. The Numobag® heals many wound conditions including diabetic ulcers, pressure ulcers, burns with limited or no scarring, necrotizing fasciitis and has no precautions for use, unlike most other wound care therapies.

The wound care market demand is driven principally by the dramatic rise in diabetic wounds, as diabetes rates soar, and the chronic wounds of the elderly (particularly bed sores), given their ever-lengthening lives. Nearly 10% or 30.3 million of the country’s population is diabetic and wound care spending on just diabetes ulcers care adds $9 billion to $13 billion to the direct yearly costs associated with diabetes. The American Diabetes Association released research on March 22, 2018, estimating the total costs of diagnosed diabetes rose to $327 billion in 2017 from $245 billion in 2012. The emergence of Numobag® has created fresh demand for nurses to help administer the treatment, and a new career opportunity for qualified medical professionals.

“I am incredibly proud of the exceptional work of the AVANTI nursing team serving the elderly patient in the Study. We recognize the looming growth in the elderly population and the immense increase in wound care needs of this population as well as the rapid rising cost, but the Numobag® treatment is highly effective and inexpensive,” said Col. Jose Negron (Retired US Air Force), President and CEO of AVANTI Technologies, Inc. “We are always on the lookout for new candidates in the medical field who want to find out more about this unique opportunity.”

A study done by the Johns Hopkins Center for Injury Research and Policy estimates that the total lifetime cost of a traumatic amputation is $509,272. This amount includes the patient’s initial hospitalization costs, the cost of follow-up hospitalizations, inpatient rehabilitative services, outpatient doctor visits, occupational therapy, physical therapy, and the costs of prostheses.

Surprisingly, current wound treatment methods do not deliver the superior treatment outcomes we have come to expect from the healthcare industry even when they come with hefty price tags. The Numobag® changes that dynamic by delivering strong patient satisfaction quickly; and its ability to preserve at-risk patients’ fingers, toes, feet and legs is lifechanging. Plus, the Numobag® is easy to administer in a range of healthcare settings and available to any patient because of the absence of use restrictions, making it an ideal solution for treating greater numbers of patients quickly and more costeffectively.

“We are gratified knowing that once the Numobag® is in wide circulation, at-risk patients will have at their disposal the wound treatment results they deserve, and their physicians should expect. Wide application of this device and treatment will lower costs and raise patient outcomes and quality of life,” added Robert Felton, President and CEO of Numotech, Inc.

The Numobag® brings disruptive technology to a costly and ever-growing market in need of it and relief to those suffering from chronic wounds, many leading to life-changing amputations.

About Numotech, Inc.

Numotech, Inc. is a premier wound-care company headquartered in Northridge, CA. Numotech specializes in the research, design, manufacture and marketing of wound care treatment and prevention products for advanced-stage wounds.

Contact No. 877-686-6832

About AVANTI Technologies, Inc.

AVANTI Technologies, Inc. is a is minority owned, Service-Disabled Veteran Owned Small Business (SDVOSB), and an 8(a) certified small business dedicated to excellence. It was founded in May 2006 to assist commercial companies and government agencies. AVANTI has grown from a single individual contractor to a fully staffed consulting business competing and positioning itself as a prime and subcontractor to government and commercial contracts. The firm provides a full range of clinical support services for the Numobag® Kit. Their credentialed and certified nurses provide on-site clinical certification, training and service for patient care in the US and internationally.

Contact No. 703-866-0482

Media Contact:

AVANTI, 703-866-0482

info@avantitech.net

Numotech Inc.

1-877-NUMOTECH (1-877-686-6832)

numotech@earthlink.net

Related Images

avanti-and-numotech.png
AVANTI and Numotech
Logo

avanti-technologies.jpg
AVANTI Technologies
Logo

numotech-inc.png
Numotech Inc.
Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/emerging-wound-care-therapy-now-heals-limbs-previously-scheduled-for-amputation-300901811.html

SOURCE AVANTI Technologies Inc.

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

6 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

7 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

10 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

10 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

10 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

10 minutes ago